127972-00-3

Usage

Uses

Used in Pharmaceutical Industry:
2-Methoxy-5-methylphenylboronic acid is used as a reactant for the preparation of selective quinazolinyl-phenol inhibitors of CHK1, which have potential applications as antitumor and radioprotectant agents. These inhibitors play a crucial role in the regulation of cell cycle checkpoints and can be employed in the development of targeted cancer therapies.
Used in Chemical Synthesis:
2-Methoxy-5-methylphenylboronic acid is utilized as a reactant in various coupling reactions, such as the Rh-catalyzed asymmetric arylation of aldehydes and stereoselective hydroarylation reactions. These reactions are essential for the synthesis of complex organic molecules, including pharmaceuticals, agrochemicals, and advanced materials.
Used in Suzuki-Miyaura Cross-Coupling:
2-Methoxy-5-methylphenylboronic acid is also used as a reactant in the Suzuki-Miyaura cross-coupling reaction, a widely employed method for the formation of carbon-carbon bonds in organic synthesis. The reaction involves the coupling of an aryl or vinyl halide with an organoboron compound, such as 2-methoxy-5-methylphenylboronic acid, to form a new carbon-carbon bond. This reaction is particularly useful in the synthesis of biologically active molecules and materials with potential applications in various industries, including pharmaceuticals, agrochemicals, and materials science.

InChI:InChI=1/C8H11BO3/c1-6-3-4-8(12-2)7(5-6)9(10)11/h3-5,10-11H,1-2H3

Upstream product

• 121-43-7 Trimethyl borate 
• 22002-45-5 2-bromo-4-methylanisole 
• 104-93-8 p-methylanizole 

Downstream Products

• 1152781-50-4 (E)-3-(2-methoxy-5-methylphenyl)-3-phenylacrylonitrile 
• 1196789-13-5 C₁₉H₁₈O₂ 
• 259209-21-7 (2-hydroxy-5-methylphenyl)boronic acid 
• 1596035-52-7 3-(2-methoxy-5-methylphenyl)-3-methylcyclopentanone 
• 1619901-70-0 3-(2-methoxy-5-methylphenyl)-3-methylcyclohexanone 
• 796975-81-0 9-(2-methoxy-5-methyl-phenyl)-anthracene 
• 4373-61-9 2-(m-tolyl)pyridine 
• 865350-37-4 2-(2-methoxy-5-methylphenyl)pyridine 

Relevant academic research and scientific papers

Evidence for Oxidative Decay of a Ru-Bound Ligand during Catalyzed Water Oxidation

In the evaluation of systems designed for catalytic water oxidation, ceric ammonium nitrate (CAN) is often used as a sacrificial electron acceptor. One of the sources of failure for such systems is oxidative decay of the catalyst in the presence of the st

Programmed multiple complexation for the creation of helical structures from acyclic phenol-bipyridine oligomer ligands

Two new multidentate ligands, H3L1 and H 4L2, possessing bipyridine-phenol repetitive units were designed so that the multi-metal complexation could produce a single-helical structure in a pre-programmed fashion. The ligands were synthesized by successive palladium-catalyzed coupling reactions. The complexation of H 3L1 with zinc(ii) and nickel(ii) acetate afforded [L 1Zn2(OAc)] and [(L1)2Ni 4](OAc)2, respectively. Each of the ligand moieties in these complexes formed a one-turn single helix. The zinc(ii) complex [L 1Zn2(OAc)] underwent a helix compression-extension motion in solution. The complexation of the H3L1 ligand with iron(iii) chloride gave a dinuclear complex [(HL1)2Fe 2Cl2] with a non-helical dimeric structure. The longer ligand H4L2 afforded a trinuclear complex [L 2Zn3(OAc)2] with a 1.5-turn single-helical structure upon complexation with zinc(ii) acetate. The reaction of the H 4L2 ligand with cobalt(ii) acetate under aerobic conditions gave a mixed valence complex [L2Co3(OAc) 3(OMe)], which had two trivalent and one divalent cobalt ions. The structural features of the trinuclear complexes significantly depended on the metals; [L2Co3(OAc)3(OMe)] had a helical pitch of 7.6 A, which was almost twice that of [L2Zn 3(OAc)2] (4.0 A).

New 5-aryl-1H-imidazoles display in vitro antitumor activity against apoptosis-resistant cancer models, including melanomas, through mitochondrial targeting

We designed and synthesized 48 aryl-1H-imidazole derivatives and investigated their in vitro growth inhibitory activity in cancer cell lines known to present various levels of resistance to proapoptotic stimuli. The IC50 in vitro growth inhibitory concentration of these compounds ranged from >100 μM to single digit μM. Among the most active compounds, 2i displayed similar in vitro growth inhibition in cancer cells independent of the cells' levels of resistance to proapoptotic stimuli and was found to be cytostatic in melanoma cell lines. Compound 2i was then tested by the National Cancer Institute Human Tumor Cell Line Anti-Cancer Drug Screen, and the NCI COMPARE algorithm did not reveal any correlation between its growth inhibition profiles with the NCI database compound profiles. The use of transcriptomically characterized melanoma models then enabled us to highlight mitochondrial targeting by 2i. This hypothesis was further confirmed by reactive oxygen production measurement and oxygen consumption analysis.

Thrombopoietin mimetics

Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.

NOVEL COMPOUNDS

The invention relates to substituted phenoxyacetic acids (I) as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.

Block copolymers of highly isotactic polypropylene via controlled Ziegler-Natta polymerization

The block copolymerization polypropylene under highly isotactic stereocontrol, using a new catalyst obtained by means of rational ligand design, was discussed. Moderately isotactic polypropylenes of very low average molecular mass in reasonable yields was

STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS

Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.

STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS

Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.

STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS

Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.

Steroid receptor modulator compounds and methods

Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.